How a century-old merger created Japan's second-largest pharmaceutical giant
In short: From the isolation of adrenaline to cutting-edge cancer therapies, Daiichi Sankyo’s evolution is a masterclass in strategic pivots. Once a collection of century-old firms, the company has transformed through massive acquisitions and high-stakes partnerships to become a global leader in oncology and antibody-drug conjugates.
The modern Daiichi Sankyo was formed in 2005 through the merger of two historic Japanese entities: Sankyo Company, Limited and Daiichi Pharmaceutical Company, Limited. The company's legacy is deeply rooted in scientific breakthroughs, such as the work of Jokichi Takamine, who served as president of Sankyo Co., Ltd. from 1913 to 1922 and patented the isolation of adrenaline.
In recent decades, the company has aggressively expanded its global footprint through complex acquisitions. In 2006, it began U.S. operations and acquired Zepharma. It later pursued a $4.6 billion deal for a majority stake in the Indian generic drug maker Ranbaxy in 2008. More recently, the company has pivoted its strategic focus toward oncology, specifically antibody-drug conjugate therapies, leading to the shutdown of its Plexxikon unit in 2022.
This strategic shift is exemplified by the success of Enhertu, an antibody-drug conjugate for cancer treatment. Developed in cooperation with AstraZeneca—which agreed to pay up to $6.9 billion for a share of sales in 2019—the drug's success helped drive the company's market value above JPY 5 trillion in early 2020. However, the journey has not been without controversy; the company previously settled allegations with the U.S. Department of Justice for $39 million regarding improper kickbacks to physicians between 2005 and 2011.
Today, the group maintains a massive international presence, including a European subsidiary headquartered in Munich, Germany, which manages development and manufacturing for 12 European countries.
Opens the Intellect+ feed with this card first. Swipe up for the next one.
Sources
- Summary by Intellect · source: Daiichi Sankyo
- Also: find-and-update.company-information.service.gov.uk — DAIICHI SANKYO UK LIMITED overview - Find and update company information - GOV.UK
To cite this card, link to https://intellectplus.co.uk/app/health-daiichi-sankyo.
How we source, check and correct cards: Editorial standards.
General information, not professional advice. Spotted an error? Flag the card or see corrections and complaints.
Intellect Plus is a visual educational discovery platform for exploring fascinating facts and ideas. Brain Food, Not Brain Rot. What is Intellect Plus?
Related
More in Future Frontier · More in Health · Latest · A–Z · All topics
